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First described in 1983, Barth syndrome (BTHS) is widely regarded as a rare X-linked genetic disease characterised
by cardiomyopathy (CM), skeletal myopathy, growth delay, neutropenia and increased urinary excretion of 3-
methylglutaconic acid (3-MGCA). Fewer than 200 living males are known worldwide, but evidence is accumulating
that the disorder is substantially under-diagnosed. Clinical features include variable combinations of the following
wide spectrum: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), endocardial fibroelastosis
(EFE), left ventricular non-compaction (LVNC), ventricular arrhythmia, sudden cardiac death, prolonged QTc interval,
delayed motor milestones, proximal myopathy, lethargy and fatigue, neutropenia (absent to severe; persistent,
intermittent or perfectly cyclical), compensatory monocytosis, recurrent bacterial infection, hypoglycaemia, lactic
acidosis, growth and pubertal delay, feeding problems, failure to thrive, episodic diarrhoea, characteristic facies, and
X-linked family history. Historically regarded as a cardiac disease, BTHS is now considered a multi-system disorder
which may be first seen by many different specialists or generalists. Phenotypic breadth and variability present a
major challenge to the diagnostician: some children with BTHS have never been neutropenic, whereas others lack
increased 3-MGCA and a minority has occult or absent CM. Furthermore, BTHS was first described in 2010 as an
unrecognised cause of fetal death. Disabling mutations or deletions of the tafazzin (TAZ) gene, located at Xq28,
cause the disorder by reducing remodeling of cardiolipin, a principal phospholipid of the inner mitochondrial
membrane. A definitive biochemical test, based on detecting abnormal ratios of different cardiolipin species, was
first described in 2008. Key areas of differential diagnosis include metabolic and viral cardiomyopathies,
mitochondrial diseases, and many causes of neutropenia and recurrent male miscarriage and stillbirth. Cardiolipin
testing and TAZ sequencing now provide relatively rapid diagnostic testing, both prospectively and retrospectively,
from a range of fresh or stored tissues, blood or neonatal bloodspots. TAZ sequencing also allows female carrier
detection and antenatal screening. Management of BTHS includes medical therapy of CM, cardiac transplantation
(in 14% of patients), antibiotic prophylaxis and granulocyte colony-stimulating factor (G-CSF) therapy.
Multidisciplinary teams/clinics are essential for minimising hospital attendances and allowing many more individuals
with BTHS to live into adulthood.
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Disease names/synonyms
– Barth Syndrome (BTHS)
– 3-methylglutaconic aciduria type 2
– X-linked cardioskeletal myopathy and neutropenia
– Cardioskeletal myopathy with neutropenia and
abnormal mitochondria
– Endocardial fibroelastosis type 2 (EFE2)
Definition
Dr Peter Barth first described a triad of cardiomyopathy
(CM), skeletal myopathy and neutropenia in 1983 in a
large Dutch kindred with high infant mortality due to in-
fection or cardiac failure [1], although the first description
of the disorder now widely known as Barth Syndrome
(BTHS) may have occurred in 1979 [2]. Kelley et al added
organic aciduria to the definition and described partial
phenotypes (isolated neutropenia and lack of CM in re-
spective cases) [3] and Spencer et al noted that 6% of 73
known Barth patients had no evidence of CM [4]. In 2010
BTHS was reported as a cause of male fetal death
resulting in miscarriage and stillbirth [5].
BTHS has a unique pathogenesis: it is the only known
human disease where the primary defect is remodeling
of cardiolipin, a phospholipid found in mitochondrial
membranes [6]. The disease affects many body systems
from fetal through to adult life, making this an import-
ant condition for obstetricians, geneticists, general
paediatricians, cardiologists and neurologists to be aware
of, especially since rapid definitive biochemical testing
has recently become available [7].
Methods
This review contains some references to previously unpub-
lished data collated by the Barth Syndrome Foundation
(BSF) Registry. The BSF Registry was approved by the
IRBs of the two relevant host institutions, the University
of Florida and Boston Children’s Hospital. Inclusion
criteria for the Registry are a diagnosis of BTHS, mu-
tation of the causative gene and the provision of in-
formed consent.
Epidemiology
151 living BTHS patients are known to the BSF world-
wide in 2012. In the USA, approximately 10 new
patients are diagnosed each year in the USA and 71
kindreds have been identified, and the BSF has estimated
a prevalence of 1/300,000-400,000 live births [8]. There
is no known racial or ethnic predilection.
Evidence is, however, growing that the disease may be
under-diagnosed. In 1999, Cantlay et al reported five
unrelated BTHS families identified from South-West
England and South Wales over a period of seven years[9]. Further case ascertainment has now identified a total
of 13 cases in current generations of 8 unrelated families
from this regional population of 6 million, implying a
prevalence potentially as high as 1/140,000 live births or
0.22/100,000 people (Orphanet category <1-9/1,000,000).
Including the cases already described, the NHS
Specialised Services Barth Syndrome Service (NSSBSS)
in the UK (2011 population: 62.6 million) has so far
identified a total of 30 unrelated families affected by the
disease in the UK, of whom 22 boys or men are alive
from 17 unrelated families. Further information about
frequency is described in the section on cardiological
aspects of the disease.
Aetiology
Genetics
The primary gene defect in BTHS is mutation in the
tafazzin (TAZ, previously termed G4.5) gene [10], com-
prising 11 exons and located on Xq28 [11,12]. The TAZ
sequence is highly conserved in evolutionary terms [13].
There are already more than 120 different mutations
identified (data from the Human Tafazzin (TAZ) Gene
Mutation and Variation Database [14]). Most are
missense mutations and small insertions or deletions,
but a minority of patients have large exon, or in one case
whole gene, deletion [15]. Frameshift mutations causing
tafazzin truncation and mutations affecting splice donor
or acceptor sites have also been identified. Mutations
have been reported in all exons of TAZ, including a vari-
ant of unknown significance in exon 5 [16]. No geno-
type/phenotype correlations have so far been identified
and there may be marked phenotypic variation between
males within a family (e.g. those described in [17]).
Data from the Human Tafazzin (TAZ) Gene Mutation
and Variation Database shows that only 13% of boys
carry de novo mutations not identified in their mother’s
somatic DNA [14]. Gonadal mosaicism has also been
documented [18], raising the small possibility that a
woman who does not herself carry mutations in her
somatic DNA may have more than one affected boy.
Although it is theoretically possible for a female to
manifest symptoms of BTHS due to skewed X-
inactivation, the only female ever described with the dis-
ease had abnormalities of both X chromosomes [19].
One was a ring form with a large deletion of the long
arm (including the Xq28 region) and the second had a
large deletion of exons 1–5 of TAZ. Problems in this pa-
tient included intrauterine growth retardation and the
development of severe dilated cardiomyopathy (DCM)
with left ventricular non-compaction (LVNC) at one
month of age.
Among 16 obligate BTHS carriers from six families
whose fibroblasts or blood cells were studied, six were





Figure 1 Abnormal Mitochondrial Appearance in BTHS Dilated
Cardiomyopathy. (A) Electron micrograph of cardiac muscle biopsy
from a patient with severe BTHS DCM. The myocyte cytoplasm
contains increased numbers of mitochondria, most being larger than
normal. Lipid is not increased but pools of non-membrane bound
glycogen are evident. (B) Higher power electron micrograph. The
mitochondria are enlarged and are crowded together, with many
touching one another. The cristae are not parallel but are stacked,
and many are in abnormal circular arrays (red arrow). The nucleus
(starred) is centrally placed, but the myofilaments, with their cross-
striations (blue arrows), are displaced to the periphery of the cell.
(C) High power photomicrograph of myocardium stained with
Masson-Trichrome stain. The myocytes are vacuolated with pale
areas around the nucleus. In some giant mitochondria are visible as
rounded, red bodies [arrows]. Such giant mitochondria are very
suggestive of mitochondrial pathology and reflect the giant
mitochondria seen on electron microscopy.
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pattern not seen in 148 normal female controls. Lesser
degrees of skewing (65–95%) were present in another
seven carriers [20] and the remaining three had a ran-
dom pattern of X-inactivation (50–65%). Both highly
skewed and non-skewed patterns of X-inactivation were
present among females within the same family. It has
been postulated that a post-inactivation selection mech-
anism might operate due to the TAZ protein causing re-
spiratory chain abnormalities or other deleterious effects
in multiple cell types [20].
Pathophysiology
TAZ encodes an acyltransferase that catalyses the remodel-
ing of cardiolipin in mitochondrial membranes [6,21-23].
The fatty acyl chain configuration of cardiolipin is tissue-
specific, with highly oxidative tissues having a cardiolipin
with four linoleoyl moieties (tetralinoleoyl cardiolipin, “L4-
CL”) as the predominant species. In mammalian cardiac
and skeletal muscle L4-CL constitutes up to 70–80% of
total cardiolipin [10,24]. TAZ mutations reduce formation
of L4-CL in favor of cardiolipin molecules of different acyl
composition and cause an accumulation of intermediate
species carrying three rather than four linoleoyl acyl groups
(monolysocardiolipins [MLCL]) [25,26]. This leads to a
markedly increased MLCL:L4-CL ratio [27] and now forms
the basis for a sensitive and apparently specific test for the
disease [7,28].
Cardiolipin has an important role in maintaining mito-
chondrial structure [29], associates with a number of
mitochondrial proteins (reviewed in [30]) and is also
involved in mitochondrial apoptosis (reviewed in [31]).
In particular, cardiolipin stabilises highly ordered re-
spiratory chain supercomplexes and optimises energy
production in mitochondria [32,33]. Evidence for a role
of cardiolipin in maintaining mitochondrial integrity is
supported by varying degrees of structural and func-
tional abnormalities of mitochondria isolated from
BTHS patients [1,23,34,35]. An example of abnormal
mitochondrial appearances from a patient with severe
BTHS DCM is shown in Figure 1.
Because research into the pathogenesis of BTHS in
humans has until recently been hampered by the inabil-
ity to make a mammalian model, most in vivo and
in vitro studies have used yeast, fruit flies, zebrafish and
cultured cells, as well as patient metabolic studies [36-
42]. In 2010, an inducible TAZ knockdown mouse model
of BTHS was developed using RNA interference tech-
nology [24,43]. TAZ knockdown for several months
from birth produces a substantial reduction in the level
of mature cardiolipin, an accumulation of MLCL species,
and an increase of the MLCL/L4-CL ratio in cardiac and
skeletal muscle. No significant cardiac effects were ap-
parent in two-month-old mice, but by eight months of
Table 1 Clinical features of Barth syndrome (common
features are asterisked)
Cardiovascular *Dilated Cardiomyopathy (DCM)
*Left Ventricular Non-compaction (LVNC)





















Endocrine & Metabolic *3-methylglutaconic aciduria





Lactic acidosis (often accompanies cardiac
failure)
Osteopenia
Gastrointestinal *Oromotor feeding problems
Episodic or chronic diarrhoea
Dysmorphic features *Deep set eyes
*Full cheeks
*Prominent ears (older boys)
Fetal Cardiomyopathy
Fetal hydrops
Male miscarriage and stillbirth
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malities of cardiac sarcomeres and mitochondria, and of
cardiac structure and function, were apparent. The latter
included left ventricular dilatation and dysfunction. The
effect on skeletal muscle was more marked, with obvious
ultrastructural changes apparent by two months. This
model holds promise for furthering our understanding
of the pathogenesis of BTHS and for testing candidate
gene or drug therapies.
Clinical description
The most widely recognised features of the disease com-
prise CM, skeletal myopathy, neutropenia, growth delay
and increased urinary excretion of 3-MGCA [3]. How-
ever, a much broader phenotype is now recognised
(Table 1). The majority of the information about BTHS
comes from individual case reports and small cases
series, although detailed analyses of 34 and 73 patients
respectively were published in 2006 [44] and 2012 [4].
Cardiological aspects
CM is the major clinical feature in BTHS, with high
prevalence in early life. Data from the BSF Registry show
that 70% of BTHS patients are recognised to have CM
in the first year (most of these presenting before six
months of age) and that all those who developed CM
did so by five years of age [4].
CM usually takes the form of DCM and can be accom-
panied by endocardial fibroelastosis (EFE, see Figure 2)
[11]. 50% of patients have prominent left ventricular
trabeculations, suggesting a form of LVNC.
Hypertrophic CM (HCM) has also been described
rarely [44,45], with both DCM and HCM being docu-
mented within a single family [44]. Left ventricular ab-
normalities may “remodel” with age; there may also be
transition between relatively dilated and hypertrophic
appearances, a feature described previously in children
with LVNC and sometimes referred to as an “undulating”
phenotype [46,47].
Unfortunately, there is often a significant delay in
diagnosing BTHS in patients with CM [44,48]. A com-
prehensive Australian study [49] suggested that 4.8% of
boys diagnosed with CM in 1987–96 had BTHS, and
7.2% of those with forms of cardiomyopathy other than
hypertrophic. Similarly, data from the Pediatric Cardio-
myopathy Registry of the USA suggests that 3–5% of all
boys with CM will have BTHS and a relatively higher
proportion of those with DCM and LVNC (personal
communication, Dr Jeffrey Towbin). This substantial
proportion suggests that all young males with unex-
plained DCM should be investigated for BTHS, espe-
cially those presenting as neonates or within the first
year. The potential for fetal onset of CM in BTHS,
which has been documented as early as 18 weeksgestation [50], has important implications which are
discussed in the section on miscarriage and stillbirth.
Initial presentation of BTHS-associated CM may
mimic viral myocarditis/CM or be precipitated by viral
infection. For example, one patient presented acutely
with severe DCM during primary infectious mononucle-
osis (personal communication, Dr Wilf Kelsall) and
A B
Figure 2 Endocardial fibroelastosis in BTHS. (A) The endocardium appears abnormally pale (starred) and (B) there is marked thickening
(arrowed) of the endocardial surface on the corresponding photomicrograph (Van Gieson staining).
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viral infections. BTHS should therefore be included in
the differential diagnosis of males presenting with DCM
of apparent viral aetiology, especially where neutropenia
is present (which could mistakenly be ascribed to sec-
ondary bone marrow suppression by viral infection). Sta-
bilisation of CM, improved overall health, and steady
growth often characterise the middle childhood years,
leading parents to report a “honeymoon phase” in their
boys. This tendency to spontaneous marked improve-
ment of BTHS features may support clinicians in their
belief that a patient in whom the diagnosis of BTHS has
been missed is recovering from a strictly viral cardiomy-
opathy. Of note, although CM is a key feature of BTHS,
not all BTHS patients have CM. Spencer et al. found
three patients (10%, aged 3, 5 and 17 years), who had
never had CM despite having affected relatives with clin-
ically significant CM [44].
There is a variable but usually overall good response to
medical therapy for cardiac failure in BTHS. Spencer et al.
[44] noted that more than 50% of patients normalised
their ejection fraction and left ventricular diastolic volume
Z Scores, although most needed to be maintained on
standard cardiac medications for DCM throughout child-
hood and into the adult years. Thus, 16 of 30 fully
evaluable BTHS patients in this study had normal left ven-
tricular ejection fractions, although 10 of these were tak-
ing at least one cardiac medication. Some patients
respond well to therapy initially but deteriorate after
months or years of stability, necessitating cardiac trans-
plantation [4]. Age at time of cardiac transplant is shown
in Figure 3.
There is also a risk of ventricular arrhythmia and sud-
den cardiac death in BTHS, which appears to be inde-
pendent of the degree of CM [11,51,52]. These
arrhythmias can occur at times of apparent good health.When studying a larger cohort, Spencer et al. found that
nine out of 70 (13%) patients had a documented ventricular
arrhythmia necessitating an implantable cardioverter defib-
rillator (ICD) [4]. Most of the documented serious
arrhythmias have been in older children but life threatening
arrhythmias have been observed in younger children, in-
cluding two deaths related to ventricular arrhythmia in ba-
bies (unpublished observations). BTHS can also present as
sudden cardiac death within families, as illustrated by a pre-
vious family history of sudden cardiac death in two BTHS
patients with documented arrhythmias [53]. Spencer et al
reported prolonged or borderline prolonged QTc in a high
proportion of BTHS patients (43%) although this did not
appear to correlate with episodes of documented ventricu-
lar arrhythmia [44]. Prolonged or borderline prolonged long
QTc has been found in children with HCM and DCM due
to other causes and may reflect the underlying cardiac
muscle abnormality, which in BTHS includes myofibrillar
disorganization [54]. Others have postulated that cardiolipin
abnormalities could impede cross-communication between
the endoplasmic reticulum and mitochondria, thus affecting
calcium handling in cardiomyocytes and cardiac conducting
cells [43].
Neutropenia
Neutropenia has been detected as a persistent or intermit-
tent feature in 90% of BTHS patients, but completely nor-
mal neutrophil counts have been present over prolonged
periods of follow-up in the remainder. It is important to
note that 30% of cases are not neutropenic at initial pres-
entation (Steward et al, manuscript in preparation). Neu-
tropenia sometimes precedes other features, and has even
been documented in a cord blood sample [1]. The neutro-
penia of BTHS takes many forms [9]; it can be severe and
chronic (with many readings <0.5 × 109/L) or truly cyc-






























Figure 3 Age at cardiac transplantation in BTHS patients. Age is shown at the time of first transplant where multiple transplant procedures
were required (data supplied by BSF). It should be noted that there were sometimes extended periods between initial listing for cardiac
transplantation and performance of procedures (data unavailable).
Clarke et al. Orphanet Journal of Rare Diseases 2013, 8:23 Page 6 of 17
http://www.ojrd.com/content/8/1/23(example shown in Figure 4). Nadirs in the neutrophil
count are associated with bacterial infection ranging from
prolonged upper respiratory tract infections, mouth ulcers,
inflamed gums and perianal dermatitis to overwhelming
sepsis and multi-organ failure. Recognition of neutro-
penia and, therefore, correct diagnosis of BTHS can be
delayed because neutrophil counts often increase to
normal or supranormal within a few days of developing
an infection [3].Figure 4 Unpredictable neutropenia in a BTHS patient. This graph sho
receiving G-CSF and had no clinical explanation for changes in neutrophil
from severe neutropenia to high normal neutrophil counts. This emphasise
presentation of male DCM as a critical determinant of whether testing for
bacterial infection in the context of a normal neutrophil count, infection ha
days previously.Concurrence of severe neutropenia, CM, mitochon-
drial dysfunction, low muscle mass and a propensity to
hypoglycaemia and lactic acidosis may all increase the
likelihood of death in response to severe bacterial infec-
tion, making BTHS an underlying diagnosis to consider
in patients dying with bacterial sepsis. Indeed, almost
half of patients with a documented cause of death in
Barth’s original paper (in a single, extended family) died
from infectious rather than cardiac complications [1].ws a routine neutrophil profile from a BTHS patient who was not
counts. It demonstrates that some BTHS patients can transition rapidly
s the importance of not using presence/absence of neutropenia at
BTHS is performed. Furthermore, BTHS patients can present with
ving commenced when severely neutropenic just one or two
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rest on bone marrow aspiration [1] (see Figure 5) and
compensatory monocytosis peripherally [3]. Although ab-
solute neutrophil counts (ANCs) for some boys fluctuate
within a relatively narrow range, others have wide and un-
predictable swings in their ANCs. This complicates treat-
ment with granulocyte colony stimulating factor (G-CSF),
which is widely used in the management of neutropenic
patients (the BSF Registry reports use of G-CSF in half of
their registered cohort of BTHS patients [4]).
The mechanism of neutropenia and infection in BTHS is
under continuing debate. Barth et al showed in their ori-
ginal studies that neutrophil function was normal [1]. It has
since been postulated that there may be increased neutro-
phil apoptosis or increased clearance of neutrophils by tis-
sue macrophages, although this has not been supported in
studies [55,56]. This has led to the hypothesis that the
defect in BTHS might operate at the level of neutrophil
precursors in bone marrow; Aprikyan et al transfected
TAZ-specific shRNA constructs into human myeloid pro-
genitor HL60 cells and showed that knockdown of TAZ
gene expression by several constructs was associated with
elevated dissipation of mitochondrial membrane potential,
compared to that of control cells transfected with
scrambled shRNA [57].Neurological aspects & skeletal myopathy
Skeletal myopathy is widely recognised in BTHS, and most
boys have at least mildly delayed gross motor milestones
[44,58]. Muscle weakness is predominantly proximal and
non-progressive during childhood, and Gower’s sign may be
present. Grip strength can be reduced, tending to improve
through the first decade and stabilise during adolescence, al-
though distal muscle weakness is not a prominent compo-
nent of the disease [44]. Patients with BTHS are able to
walk but often find normal activities, such as kicking a ball
or running, difficult. The evolution of disabling myopathy
has been described at between 43 and 50 years in one man
subsequently diagnosed with BTHS; his electromyogram100µm
Figure 5 Bone Marrow Appearances in BTHS. A bone marrow
aspirate from a patient with BTHS showing typical myelocyte arrest.
There is an excess of monocytes and absence of mature neutrophils.was consistent with severe, chronic myopathy and creatine
phosphokinase was slightly elevated [17].
Boys tend not to have classic myopathic facies, or in-
volvement of extra-ocular or diaphragmatic muscles.
Poor tone can result in lumbar lordosis. The typical
marked reduction in muscle bulk, and therefore much
lower than expected weight-for-height, can result in mis-
diagnosis as “failure to thrive”. Easy fatigability is a major
problem in BTHS and some boys use mobility aids to
conserve energy. Limitations of functional capacity are
marked and likely multifactorial in nature, including
limited cardiac reserve and diminished extraction/util-
isation of oxygen by skeletal muscles [59].
Screening patients with unexplained mitochondrial
myopathy has already identified one BTHS patient [28].
Diagnostic investigations for BTHS should therefore be
considered in any boy with idiopathic myopathy or
“mitochondrial disease” where no cause can be found
on routine screening of relevant genes. Investigation of
myopathy by invasive muscle biopsy has yielded a var-
iety of results including increased fat vacuolisation/at-
rophy of type I fibres and increased subsarcolemmal
spaces, normal or abnormal mitochondria, and variable
changes in respiratory chain complexes [1,11,17,60-62].
It is, however, important to note that muscle biopsy
has no role in the elective diagnosis of a patient with
suspected BTHS.
BSF Registry self-reported data indicates that 48% of
boys aged 7 years or older had some form of learning
disability and that 33% required some form of special
education [4]. A small study demonstrated significantly
weaker visuospatial and visual motor scores on neuro-
psychological testing, and a non-significant tendency to-
wards lower scores in mathematics, than in a control
population [63]. Detailed neuropsychological assessment
of a larger patient group is currently being performed
(personal communication, Dr. Vanessa Garratt).
Stroke is also a significant risk in BTHS patients,
mostly in the context of severe cardiac failure and pos-
sibly related to clot formation in the increased ventricu-
lar trabeculations often seen in BTHS. Middle cerebral
artery occlusion has been reported in one 18-year-old
patient with severe DCM [64] but 12 other patients are
known to the BSF, including one who developed fatal
clots shortly after going onto a Berlin Ventricular Assist
Device (unpublished observations, Valerie Bowen).
Metabolic aspects
Many boys show a five to 20-fold increased level of
3-MGCA on quantitative analysis of urinary organic
acids and BTHS is therefore also known as ‘type II 3-
methylglutaconic aciduria’. 3-methylglutaric acid and 2-
ethyl-hydracrylic acid levels are also increased [3]. However,
cases have been reported where urinary 3-MGCA levels
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[45,50,61,65-67] and levels may vary considerably even
within a 24 hour period [9]. 3-MGCA is also elevated in a
collection of disorders of widely varying phenotype
(reviewed in [68]), making this a test with poor diagnostic
specificity.
Although many boys with BTHS never experience signifi-
cant metabolic problems, a range of metabolic abnormalities
have been reported which may alert clinicians to consider-
ation of the diagnosis. These include low pre-albumin levels
(79%), decreased low density lipoprotein cholesterol (56%),
hypocholesterolaemia (24%), mildly elevated creatine kinase
(15%), lactic acidosis, hypoglycaemia, reduced plasma
carnitine levels, raised serum transaminases and mild
hyperammonaemia ([3,44,69]; incidence figures taken from
reference [44]). Lactic acidosis and hypoglycaemia appear to
be more common in the neonatal period and infancy. Sev-
eral cases of acute metabolic decompensation and death
have been described in neonates [52,69].
Ongoing studies on the intermediary metabolism of
BTHS suggest that secondary abnormalities of citric acid
cycle function sufficiently affect anaplerosis and amino acid
metabolism to cause inadequate muscle protein synthesis
(unpublished observations, Dr Richard Kelley). Various
attempts at targeting the metabolic derangements in BTHS
have been tried, including the use of L-carnitine [70] or
pantothenic acid [71]. Whilst some patients with BTHS are
able to tolerate pharmacologic doses (50–100 mg/kg/d) of
L-carnitine, there is no evidence that these amounts are
therapeutic and carnitine is therefore not usually given un-
less total plasma carnitine levels are low. Most patients
treated with pantothenic acid supplements have failed to
show benefit (representative examples reported in [72]).
More recently, the identification of consistently low levels
of specific amino acids have led to dietary supplementation
with arginine and other amino acids but there is as yet no
published data on these observations or treatment.
Growth delay
Growth delay is seen in both BTHS patients [4] and cellular
models of the condition (reviewed in [73]). Hypothetically,
many factors could contribute to growth delay, including
poor nutrition, diarrhoea, CM, sore mouth/gums and recur-
rent infection. However, to a considerable extent the growth
pattern of BTHS conforms to that of typical constitutional
growth delay with delayed puberty. Longitudinal growth
data of a representative population (patients attending the
NSSBSS clinics) is shown in Figure 6. Delayed bone age has
been present in all boys attending this clinic, ranging be-
tween 8 months and 2 years 6 months, although more ex-
treme delay has been noted (as exemplified by the boy
whose wrist X-ray is shown in Figure 7).
Spencer et al [44] found that 58% of patients less than
18 yrs were below the 5th centile for weight and at orbelow the 5th centile for height. By contrast, those older
than 18 years had a mean weight on the 13th percentile
(range <1–63%) but mean height on the 50th percentile
(range 8–90%). This change is effected by a delayed
growth spurt at 15–21 years of age, which can take boys
rapidly from a low growth centile to even above their
midparental height in a few cases. This may be accompan-
ied by worsening of cardiac function. The period of rapid
pubertal growth often occurs without commensurate in-
crease in food intake, with the result that many boys may
appear to be relatively emaciated, and supplemental
feeding via nasogastric or gastrostomy tubes has some-
times been given. Normalised growth curves for BTHS
patients have been prepared from BSF Registry data [4].
A study of 22 BTHS patients aged between 4 months and
24 years reported subnormal levels of growth hormone
(GH) below 14.4 years, but levels higher than controls
above this age, most marked at 19–20 years [74]. Insulin-
like growth factor-1 (IGF-I) deficiency has been reported;
as expected for constitutional growth delay, the patient had
normal GH release and no other sign of pituitary dysfunc-
tion. One additional BTHS patient with typical constitu-
tional growth delay and low IGF-1 level was treated with
GH for one year, but showed no change in growth velocity.
However, two boys with BTHS who showed atypical
growth arrest in their middle childhood years met standard
criteria for GH deficiency and responded to GH treatment
(unpublished observations, Dr Richard Kelley). This occur-
rence of two cases of bona fide central GH deficiency in
such a small patient cohort suggests that there could be an
increased risk for central GH deficiency in BTHS.
It should be noted that not all children display poor
growth. Spencer et al documented that nearly 25% of boys
younger than 18 years had weight above the 20th percent-
ile and more than 50% had normal or increased BMI [44].
Boys with BTHS with BMI greater than the 25th centile
have markedly abnormal truncal adiposity (unpublished
observations, Nicol Clayton & Dr Richard Kelley).
Feeding problems
There is little published information about feeding
problems in BTHS, but many boys are slow to transition
to solid food, and have a degree of oromotor weakness,
leading to a sensitive gag reflex, poor chewing skills,
extended mealtimes and small portion sizes. When ac-
companied by slow growth along the lower centiles and
concern about hypoglycaemia, this situation often leads
to supplemental feeding. The BSF Registry reports that
one third of BTHS patients have required a nasogastric
or gastrostomy tube for feeding at some stage [4].
Miscarriage & stillbirth
The first case of BTHS detected prenatally was
published in 1997 [75]. It is now known that CM due to
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(See figure on previous page.)
Figure 6 Longitudinal growth data. Growth data from 23 patients attending the NSSBSS clinics, plotted as weight and length respectively in
the first two years (A and B) and weight and height from 2–21 years (C and D). One patient followed to 20 years underwent cardiac
transplantation at 20 months and another one followed to 21 years has received both cardiac and renal transplants (at 2 and 15 years
respectively). The three oldest patients illustrated in (D) demonstrate constitutional growth delay with continued growth to as late as 21 years.
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http://www.ojrd.com/content/8/1/23genetically proven BTHS can develop as early as 18 -
weeks gestation [50]. A survey published in 2010 showed
that one third of BTHS families in the UK have a history
of excessive male fetal and neonatal losses, establishing
that BTHS could lead to isolated or recurrent male fetal
death [5]. In six families, nine babies were stillborn, 14
died in early life, and a further nine miscarriages were
suspicious for BTHS. Importantly, there were no female
losses from the second trimester through to term in
these families, and one woman (since proven to be a
BTHS carrier) lost all three of her male babies as second
trimester miscarriages or stillbirth at term. Combined
with evidence of CM in utero and age-related expression
of TAZ, this provides support for a role of TAZ in em-
bryonic, fetal and neonatal life [50,75].
Further evidence comes from zebrafish and mouse
TAZ knockdown models. In zebrafish, studies showedFigure 7 Delayed Bone Age. This patient showed severe
constitutional growth delay with a bone age of 8.3 years on the
Tanner and Whitehouse scale at a chronological age of 13.2 years.that TAZ RNA was expressed at high levels in many
tissues in the early stages of embryogenesis, becoming
restricted to the heart in late gestation, and that TAZ ex-
pression was essential for normal development [39]. In
the mouse model of BTHS, if females are fed doxycyc-
line (resulting in gene knockdown) from the start of ges-
tation throughout pregnancy, their offspring develop
early cardiac diastolic dysfunction, hypertrabeculation
and noncompaction [76]. BTHS therefore appears to be
an important differential diagnosis of male fetal loss
where there is evidence of hydrops and CM.
Dysmorphology
Boys with BTHS show remarkable similarities in facial
features, especially from infancy to early adolescence [77].
In early childhood, the face is round with full cheeks and
an overall “cherubic” appearance (see Figure 8), whereas
after the first decade and especially after puberty, the head
and face become narrowed and the ears more prominent.
During adolescence, there is development of gynoid
proportions and, in some, relative truncal fat distribution.
Diagnosis and diagnostic methods
Historically, diagnosis of BTHS has principally relied on
identifying boys with the combination of cardioskeletal
myopathy, neutropenia and 3-MGCAciduria. However,
reliance on this diagnostic triad has been fraught with
problems. Firstly, one third of patients will not be neu-
tropenic at presentation, and some boys will never dis-
play neutropenia. Secondly, the urine level of 3-MGCA
may be normal or, being only mildly to moderately
increased, is sometimes missed by laboratories that do
not perform quantitative studies or are not sensitive to
the significance of mild to moderate 3-MGCAciduria.
Such problems in diagnosis have now been partially over-
come by the development of a straightforward diagnostic
assay measuring the MLCL:L4-CL ratio [26,28,78], which
can be applied to a variety of cells and tissues, including
stored dried bloodspot cards [7]. This ratio has shown
100% diagnostic sensitivity and specificity for BTHS
[7,28,78] but to date is only available in a few centres world-
wide. Cardiolipin ratio analysis allows definitive diagnosis at
a much lower cost than genetic testing, and could now be
considered a routine component of the testing of males
with idiopathic DCM, especially those presenting in the
neonatal or infant period. Abnormal cardiolipin ratio
testing can then be followed up with targeted genetic
Figure 8 Facial Appearance. Young boys with BTHS have consistent facial features with a tall, broad forehead, round face with full cheeks,
prominent ears and deep-set eyes. These features become less evident during puberty and into early adulthood, although the eyes may remain
deep set and ears prominent [77].
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http://www.ojrd.com/content/8/1/23testing for TAZ mutations. In addition, if stored tissue
(e.g. fibroblasts, dried bloodspots) is available, retrospective
diagnosis can be attempted by cardiolipin ratio testing,TAZ
analysis or a combination of the two. It is also important to
note that most commercially available mutation screening
panels for DCM and LVNC will include screening for a
TAZ mutation (although this should be confirmed with the
individual laboratory).
Clinical scenarios where exclusion of BTHS should be
considered are summarised in Table 2 and the relevant
diagnostic tests available are described in Table 3.
Antenatal diagnosis and genetic counselling
Clinical genetic assessment has a major role in assessing
potential BTHS patients/families. BTHS should be
strongly suspected where the parents are healthy but thereis a history of DCM, early death or male miscarriage/still-
birth affecting male siblings or male antecedents related
through the maternal line of the family.
Once the causative mutation has been identified, pedi-
gree analysis, cascade testing and the offer of antenatal
diagnosis to proven carriers should be given high prior-
ity. If the mother of an index patient is shown to be a
carrier, this will concentrate on female relatives in her
family line and brothers with a suspicious history of ill
health (this may have caused problems in early child-
hood but subsequently improved). All the daughters of a
BTHS male would be expected to be obligate carriers
but none of his sons.
Despite an isolated report of prenatally detected BTHS
[75], Bleyl et al. showed that fetal ultrasound was not re-
liable in predicting LVNC [79] and indeed there is no
Table 2 Clinical indications for exclusion of BTHS
Recommendations for exclusion of BTHS Clinical scenario
Consider routinely • Fetal Cardiomyopathy
• Male children with DCM ± EFE, especially those with neonatal / infantile onset
• X-linked cardiomyopathy of any type (DCM, LVNC, HCM)
• Cardiomyopathy with LVNC or LV modeling defects
• Cardiac arrest / cardiac arrhythmia with echocardiographic abnormality consistent
with BTHS
Consider with relevant accompanying features
e.g. X-linked family history, growth failure, feeding
problems, delayed motor milestones, lethargy/easy fatigue:
• Multiple male miscarriages / stillbirths / unexplained deaths
• Neonatal / infantile hypoglycaemia / lactic acidosis
• Viral cardiomyopathy
• Unexplained neutropenia, mitochondrial disease or proximal myopathy
• Serious unexplained bacterial sepsis
• Severe feeding problems, persistent episodes of vomiting / diarrhoea
• Growth failure / delayed puberty / delayed bone age
• Unexplained ventricular arrhythmia or prolonged QTc interval
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delivery of affected fetuses can improve outcome. In
BTHS families, molecular genetic analysis using DNA
from chorionic villus sampling and/or amniocentesis
preceded by fetal sexing using free fetal DNA analysis
on maternal blood to identify male pregnancies will
allow definitive antenatal genetic diagnosis [80,81].
Differential diagnosis
The huge variety of clinical features attributed to BTHS
means that the differential diagnosis is potentially very
wide. This is especially true for those boys with a partial
phenotype who present with only one or a few clinical
features of BTHS. However, key differential diagnoses
include:Table 3 Diagnostic tests for BTHS
Test Description
Urinary 3-MGCA Testing Most cases of BTHS will
excretion on quantitative
of the diagnosis is requi
N.B. Multiple reports sugg
testing in patients later sh
candidate patient must th
order to reliably exclude B
Monolysocardiolipin/Cardiolipin (MLCL:L4-CL)
Ratio Testing (where available)
This test offers the best
diagnostic sensitivity and
a few laboratories [7,28,7
Testing can be performe
or dried blood spots.
TAZ Gene Sequencing: TAZ gene sequencing ca




suspected index patients Hereditary cardiomyopathy (including autosomal
dominant, autosomal recessive, X-linked and
mitochondrial forms)
 Dilated cardiomyopathy of endocrine or metabolic
aetiology. The most important differential diagnosis
is DCM with ataxia (DCMA) syndrome, an
autosomal recessive BTHS-like disorder first
described in the Canadian Dariusleut Hutterite
population in 2006 [82] and more recently
diagnosed in a pair of Finnish brothers [83]. This is
caused by homozygous mutations in the DNAJC19
gene which encodes a protein previously localised to
mitochondria in cardiac myocytes and thought to
play a role in mitochondrial matrix protein import
[84]. Males and females are affected, with a highbe suggested by the finding of a 5-20 fold elevation of 3-MGC
urinary organic acid analysis. As this test is non-specific, confirmation
red by TAZ mutation/cardiolipin ratio testing.
est that urinary 3-MGCA levels may be normal on single specimen
own to have BTHS [45,50,61,65-67]. A negative 3-MGCA test in a
erefore be confirmed by cardiolipin ratio testing or TAZ sequencing in
THS.
combination of speed, cost and diagnostic accuracy, with 100%
specificity reported in several series, but is currently only available in
8].
d on blood specimens (sent by routine postal services), stored tissue
n be targeted selectively to those with an abnormal cardiolipin ratio
andidate patients where cardiolipin testing is not available. It is
d as one of the genes sequenced simultaneously in sequencing
of cardiomyopathy. It also has an important place in the investigation
e appropriate samples for biochemical testing are not available from
.
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cardiomyopathy with prolonged QTc interval,
skeletal myopathy, microcytic anaemia, non-
progressive cerebellar ataxia, testicular dysgenesis,
growth failure and 3-MGCA (termed type V
methylglutaconic aciduria) and 3-methylglutaric
aciduria. Neutropenia has not been described.
 Nutritional cardiomyopathy (including thiamine,
selenium, carnitine and vitamin D deficiency)
 Idiopathic mitochondrial disease
 Cyclic or idiopathic neutropenia
Management including treatment
Standard heart failure management has included the use of
angiotensin converting enzyme inhibitors, beta blockers,
digoxin and diuretics, although there are no published stud-
ies analyzing the efficacy of these. Many BTHS patients
appear to respond to this conventional medical therapy and
no specific cardiac medications have been shown to be
of particular value or risk. Long term surveillance for
arrhythmias is recommended in all patients. The finding of
ventricular arrhythmia or symptoms such as syncope
should prompt additional testing and consideration of
placement of an ICD.
14% of patients in the BSF Registry have required car-
diac transplantation [85]. This procedure has generally
shown good results despite the high pre-operative risk
[48], although there is one reported case of an unusual
non-Epstein-Barr virus-associated T-cell lymphoma after
cardiac transplantation which resulted in the death of the
patient due to intolerance of chemotherapy [86]. The Ber-
lin EXCOR left ventricular assist device has been used to
bridge the gap until a donor heart can be sourced in some
boys with severe cardiac dysfunction [47]. Major risks in-
clude stroke due to clots forming within the chambers
and infection aggravated by neutropenia.
Most patients, even those with fully adequate nutri-
tion, will show a decreasing growth velocity during their
first two years. Provided that patients with BTHS grow
along or parallel to a low percentile after the third year,
their diets should not be augmented with the aim of
driving them back towards their birth weight and length
percentiles, since this often produces vomiting, can
cause longstanding food aversion and may contribute to
development of truncal obesity. Cornstarch supplements
may be used at bedtime (as in patients with glycogen
storage disease) to provide an alternative source of glu-
cose production and so limit the degree of muscle wast-
ing resulting from overnight fasting [87].
Patients with symptomatic neutropenia are usually
treated with a combination of subcutaneous G-CSF and
prophylactic antibiotics. G-CSF is typically commenced at
a dose of 2–3 μg/kg/dose at a frequency varying between
twice weekly and alternate daily according to the severityof their neutropenia, allied infections and drug responses
(Dr Colin Steward, manuscript in preparation). The aim is
to raise the average of the neutrophil count rather than to
permanently normalise it – since trying to achieve the lat-
ter can lead to major neutrophilia due to superimposition
of G-CSF effects on the highly variable neutrophil count
typical of BTHS patients. Many patients will show marked
symptomatic improvements (prevention of aphthous
ulcers and sore gums, reductions in bacterial infections
and sometimes reduced lethargy). Prophylactic antibiotics
are frequently used to reduce the risk of serious infections,
especially in boys who are intermittently neutropenic but
not receiving G-CSF.
No drug or food supplement has so far been shown to
be conclusively beneficial. The value of pantothenic acid
[71] has not been proven and single reported patients
have worsened soon after introduction of L-carnitine
supplements or deteriorated whilst on supplementation
[71,72].
In addition to medical and surgical intervention, many
other specialists play a role in the management of BTHS
including physiotherapists and occupational therapists,
speech and language therapists, psychologists and educa-
tional support workers. Patients with this complex dis-
ease are therefore best managed by a multidisciplinary
team approach within specialised clinics.
Prognosis
Historically, most boys with BTHS died during fetal
life through to infancy from either heart failure or
overwhelming infection. A paper published in 2005 showed
that 70% of retrospectively-diagnosed brothers of BTHS
patients had died before the diagnosis was established in
the family. This contrasted with patients identified pro-
spectively and managed proactively, for whom mortality
had fallen to just 10% [88], emphasising the importance of
early diagnosis. Despite this emphasis on early diagnosis,
data from the BSF Registry shows a mean lag time of 3.3 -
years between first presentation and diagnosis [85].
The BSF have collated data on the age of known BTHS
patients (see Figure 9). In the year of its inception (2000),
BSF knew of 41 living males with BTHS, of whom only 4/
41 (10%) were over 15 years of age. By 2011 this had
climbed to 53/148 (36%, data courtesy of BSF). Although
likely to be subject to a degree of ascertainment bias, these
figures suggest that males diagnosed with BTHS are sur-
viving longer in response to improvements in supportive
care. The oldest reported patient with BTHS is currently
in his 50’s [75].
Unresolved questions
There have been many major advances in our
understanding of BTHS, especially in terms of aetiology,
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Figure 9 Age distribution of BTHS patients. The age distribution of living BTHS cases known to the BSF in 2000 (A) and 2011 (B).
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in areas such as the variability of clinical severity with
age in individual patients or between family members,
lack of phenotype/genotype correlation and the exact
mechanism by which altered cardiolipin metabolism
causes BTHS. This has hindered understanding of the
unusual features of BTHS (such as the waxing and wan-
ing of neutropenia, fluctuating severity of cardiomyop-
athy and constitutional growth delay), as well as the
approach to managing patients. There is also no defini-
tive epidemiological data on the frequency of BTHS.
Conclusions
For 25 years after its first description, BTHS was generally
regarded as an extremely rare disease. It was usually only
considered when patients presented with a combination
of CM, neutropenia and excessive urinary excretion of
3-MCGA. We have described how this only outlines a
partial view of the disease, which affects many systems
from fetal through to adult life. We recommend that in-
vestigation for BTHS should now be regarded as essential
in male neonates, babies and young boys presenting with
idiopathic DCM or LVNC, and in males with unexplainedventricular arrhythmia or sudden death. It should also be
considered in the following scenarios: boys with idiopathic
neutropenia (particularly where this is intermittent and
unpredictable); those with unexplained severe bacterial
sepsis accompanied by features such as growth delay, un-
explained failure to thrive or motor delay; in boys with
persistent unexplained feeding problems; “idiopathic”
mitochondrial disease with myopathy and miscarriage/
stillbirth where it is clear that either an X-linked pattern
of inheritance and/or CM is present. Early identification
allows wider family screening and antenatal counselling,
as well as allowing disease appropriate management,
which can radically reduce early mortality.
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